OBJECTIVES: In Asia, individuals with hemophilia are often treated with cryoprecipitate as it is considered a less expensive option. However, the risk of acquiring blood-borne infections is higher with cryoprecipitate than with factor concentrates. Any acquisition cost savings that occur with the use of cryoprecipitate may be offset by greater total healthcare costs to treat transmissible viruses. METHODS: A literature review was conducted to obtain estimates of the prevalence of HIV, HBV and HCV in the blood supply and costs of treating the subsequent diseases. Data from international health organizations, local experts in the treatment of hemophilia, and the local Red Cross Society was utilized. This data forms the basis of an economic and outcomes model for hemophilia treatment in this Asian country. RESULTS: Based on the data identified, the risk of exposure to the blood-borne infections in hemophiliacs treated with cryoprecipitate is substantial: 3%, 6% and 12% at 5, 10 and 20 years respectively for HIV. Risk for developing hepatitis infection was higher. The discounted cost of treating the three infectious diseases is substantial. For patients treated with cryoprecipitate total treatment costs were $26,575 and $64,291.06 at 10 and 20 years. For patients treated with factor concentrate equivalent costs were $32,200 and $64,401. CONCLUSIONS: Over time, the acquisition cost savings associated with cryoprecipitate use, compared to factor concentrate, disappears as the costs for treating transmissible viruses in infected patients increases.